Published in

Society of Nuclear Medicine, Journal of Nuclear Medicine, 7(52), p. 1073-1078, 2011

DOI: 10.2967/jnumed.110.085142

Links

Tools

Export citation

Search in Google Scholar

Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas

Journal article published in 2011 by Damian Wild, Emanuel Christ ORCID, Martyn E. Caplin, Tom R. Kurzawinski, Flavio Forrer, Michael Brändle, Jochen Seufert, Wolfgang A. Weber, Jamshed Bomanji, Aurel Perren ORCID, Peter J. Ell, Jean Claude Reubi
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
  • If required by funding agency
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Glucagon-like peptide-1 (GLP-1) receptor imaging is superior to somatostatin receptor subtype 2 (sst(2)) imaging in localizing benign insulinomas. Here, the role of GLP-1 and sst(2) receptor imaging in the management of malignant insulinoma patients was investigated.